{"abstract":"This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR Part 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant to Mitchell Woods Pharmaceuticals, LLC, of an exclusive commercialization license to practice the inventions embodied in the following U.S. Patent Applications (and all continuing applications and foreign counterparts): Serial No. 61/651,961, filed May 25, 2012, entitled, \"Methods of Regulating Cannabinoid Receptor Activity-related Disorders and Diseases\" [HHS Reference E-139-2012/0-US-1]; Serial No. 61/ 789,629, filed March 15, 2013, entitled, \"Methods of Regulating Cannabinoid Receptor Activity-related Disorders and Diseases\" [HHS Reference E-139-2012/1-US-1]; Serial No. 61/312,642, filed March 10, 2010, entitled, \"The Use of Fenoterol and Fenoterol Analogues in the Treatment of Glioblastomas and Astrocytomas\" [HHS Reference E-013- 2010/0-US-01]; Serial No. 60/837,161, filed August 10, 2006, entitled, \"Preparation of R,R-Fenoterol and R,R-Fenoterol Analogues and Their Use in Congestive Heart Failure\" [HHS Reference E-205-2006/0-US-1]; and Serial No. 60/927,825, filed May 3, 2007, entitled \"Preparation of R,R-Fenoterol and R,R-Fenoterol Analogues and Their Use in Congestive Heart Failure\" [HHS Reference E-205-2006/1-US-1]. The patent rights in these inventions have been assigned or exclusively licensed to the Government of the United States of America. The prospective exclusive commercialization license territory may be worldwide, and the scope may be limited to the following two fields of use:","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2013/06/20/2013-14645.html","cfr_references":[],"citation":"78 FR 37234","comment_url":null,"comments_close_on":"2013-07-05","correction_of":null,"corrections":[],"dates":"Only written comments or applications for a license (or both) which are received by the NIH Office of Technology Transfer on or before July 5, 2013 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2013-14645","effective_on":null,"end_page":37234,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2013/06/20/2013-14645.xml","html_url":"https://www.federalregister.gov/documents/2013/06/20/2013-14645/prospective-grant-of-exclusive-license-start-up-commercial-license-for-the-development-of-fenoterol","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2013-14645?publication_date=2013-06-20","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2013-06-20/2013-14645/mods.xml","not_received_for_publication":null,"page_length":1,"page_views":{"count":150,"last_updated":"2026-09-21 08:15:05 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2013-06-20/pdf/2013-14645.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2013-14645.pdf?1371646533","publication_date":"2013-06-20","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2013/06/20/2013-14645.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"supporting_documents":[],"comments_url":"https://www.regulations.gov/docketBrowser?rpp=50&so=DESC&sb=postedDate&po=0&dct=PS&D=NIH_FRDOC_0001","supporting_documents_count":0,"docket_id":"NIH_FRDOC_0001","regulation_id_number":null,"title":"Recently Posted NIH Rules and Notices.","checked_regulationsdotgov_at":"2013-07-10T08:07:48Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":37234,"subtype":null,"title":"Prospective Grant of Exclusive License: Start-Up Commercial License for the Development of Fenoterol and Fenoterol Analogues for the Treatment of Brain, Liver, and Pancreatic Cancers and Congestive Heart Failure","toc_doc":"Development of Fenoterol and Fenoterol Analogues, etc.","toc_subject":"Prospective Grants of Exclusive Licenses:","topics":[],"type":"Notice","volume":78}